Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.
Type:
Grant
Filed:
November 1, 2021
Date of Patent:
February 6, 2024
Assignee:
President and Fellows of Harvard College
Abstract: The present disclosure provides fusion polypeptides comprising serum albumin binding single domain antibody and GDF15, the polypeptide complexes thereof. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
Type:
Grant
Filed:
June 4, 2021
Date of Patent:
January 23, 2024
Assignee:
Q32 Bio Inc.
Inventors:
Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
Abstract: Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells.
Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
Abstract: The present disclosure concerns antibodies and antibody fragments binding to citrullinated proteins (ACPA), and their use in prevention and treatment of autoimmune diseases, specifically rheumatoid arthritis (RA).
Type:
Grant
Filed:
November 22, 2018
Date of Patent:
January 9, 2024
Assignee:
Vacara AB
Inventors:
Rikard Holmdahl, Theo Rispens, Bingze Xu, Changrong Ge
Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.
Type:
Grant
Filed:
November 9, 2020
Date of Patent:
January 2, 2024
Assignees:
Pfizer Inc., The Brigham And Women's Hospital, Inc.
Inventors:
Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
Abstract: A method for in vitro activation and/or expansion of immune cells is provided, including the steps of: a) providing magnetic particles having multi-protrusive surface modified with at least one type of immuno-inducing substance, in which each magnetic particle includes a copolymer core, a polymer layer, a magnetic substance layer, and a silicon-based layer from the inside to the outside; b) providing a cell solution including at least one type of immune cell in the cell solution; and c) bringing the magnetic particles in contact with the cell solution, in which the at least one type of immuno-inducing substance on the surface of the magnetic particle activates and/or expands the at least one type of immune cell in the cell solution.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
January 2, 2024
Assignees:
Industrial Technology Research Institute, National Taiwan University Hospital
Abstract: The invention is directed to a protein construct comprising a scaffold protein into which an IgE epitope containing motif is inserted or substituted. The protein construct may be used as an antigen, immunogen or vaccine to induce immune responses against IgE in a vaccinated subject thereby reducing the severity of allergic phenomena associated with IgE. The invention is also directed to a method for designing such a protein construct and expressing it using recombinant DNA methods.
Abstract: The present invention relates to a binding molecule, in particular an antibody or binding fragment thereof, capable of activating FXII, which binds to the proline rich domain of FXII. In particular, the invention is directed to FXII activating antibodies or binding fragments thereof which binds to the proline rich domain of FXII. The invention also encompasses the use of the binding molecule directed to the proline rich domain of FXII as blood coagulation activator, e.g. in diagnostic blood coagulation tests. Corresponding methods and blood coagulation test are also encompassed.
Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
December 19, 2023
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Mark Karbarz, Pamela B. Conley, Genmin Lu
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Type:
Grant
Filed:
May 7, 2020
Date of Patent:
December 12, 2023
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
Abstract: The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
December 5, 2023
Assignee:
Washington University
Inventors:
Michael S. Diamond, Daved Fremont, Haiyan Zhao, Estefania Fernandez, Derek Platt, Christopher Nelson
Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.
Type:
Grant
Filed:
April 6, 2020
Date of Patent:
November 28, 2023
Assignees:
HOBIT GENOMIX, INC., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
Abstract: Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.
Inventors:
Scott Lauder, Tom Purcell, Sridhar Govindarajan, Taco Willem Kuijpers, Diana Wouters, Maria Clara Brouwer, Richard Benjamin Pouw, Taede Rispens, Ilse Jongerius, Gillian Dekkers
Abstract: The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptide to a subject having a blood coagulation disorder and having endogenous Factor VIII (FVIII), wherein the activity level of endogenous FVIII in said subject before treatment with said polypeptide is reduced relative to the activity level of FVIII in normal human plasma (NHP) provided that the activity level of endogenous FVIII in said subject is at least 0.5% of the activity level of endogenous FVIII in normal human plasma (NHP), wherein the polypeptide is capable of binding to endogenous FVIII and wherein the endogenous FVIII level is increased following administration of said polypeptide.
Type:
Grant
Filed:
November 10, 2017
Date of Patent:
November 14, 2023
Assignee:
CSL BEHRING LENGNAU AG
Inventors:
Stefan Schulte, Thomas Weimer, Sabine Pestel, Hubert Metzner, Steve Dower
Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
Type:
Grant
Filed:
June 4, 2018
Date of Patent:
November 14, 2023
Assignees:
MERCK PATENT GMBH, ABLYNX NV
Inventors:
Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
Abstract: The present disclosure relates to methods for generating broadly neutralizing bovine anti-HIV Env antibodies, compositions comprising the broadly neutralizing bovine antibodies, and methods of treatment or prevention of HIV using the broadly neutralizing bovine antibodies. In certain embodiments, a broadly neutralizing bovine antibody comprises a polyclonal F(ab) or F(ab?)2 fragment. In certain embodiments, a broadly neutralizing bovine antibody comprises a humanized bovine monoclonal antibody.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
October 24, 2023
Assignees:
International AIDS Vaccine Initiative, The Scripps Research Institute, THE TEXAS A&M UNIVERSITY SYSTEM
Inventors:
Devin Sok, Dennis R. Burton, Vaughn V. Smider, Ian Wilson, Michael Criscitiello, Waithaka Mwangi
Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
October 17, 2023
Assignee:
IMCYSE SA
Inventors:
Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
Abstract: The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers).